FR2213058A1 - - Google Patents

Info

Publication number
FR2213058A1
FR2213058A1 FR7346979A FR7346979A FR2213058A1 FR 2213058 A1 FR2213058 A1 FR 2213058A1 FR 7346979 A FR7346979 A FR 7346979A FR 7346979 A FR7346979 A FR 7346979A FR 2213058 A1 FR2213058 A1 FR 2213058A1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7346979A
Other versions
FR2213058B1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allen and Hanburys Ltd
Original Assignee
Allen and Hanburys Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allen and Hanburys Ltd filed Critical Allen and Hanburys Ltd
Publication of FR2213058A1 publication Critical patent/FR2213058A1/fr
Application granted granted Critical
Publication of FR2213058B1 publication Critical patent/FR2213058B1/fr
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D253/075—Two hetero atoms, in positions 3 and 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FR7346979A 1973-01-04 1973-12-28 Expired FR2213058B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB55373*[A GB1457873A (en) 1973-01-04 1973-01-04 Imidazotriazines

Publications (2)

Publication Number Publication Date
FR2213058A1 true FR2213058A1 (fr) 1974-08-02
FR2213058B1 FR2213058B1 (fr) 1977-07-01

Family

ID=9706420

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7346979A Expired FR2213058B1 (fr) 1973-01-04 1973-12-28

Country Status (19)

Country Link
US (1) US3941785A (fr)
JP (1) JPS4995994A (fr)
AT (1) AT336029B (fr)
AU (1) AU474078B2 (fr)
BE (1) BE809369A (fr)
CA (1) CA1005057A (fr)
CH (1) CH618170A5 (fr)
DE (1) DE2364076A1 (fr)
ES (1) ES422001A1 (fr)
FI (1) FI57260C (fr)
FR (1) FR2213058B1 (fr)
GB (1) GB1457873A (fr)
IE (1) IE38681B1 (fr)
IL (1) IL43872A (fr)
LU (1) LU69099A1 (fr)
NL (1) NL7400095A (fr)
NO (1) NO140301C (fr)
SE (1) SE408179B (fr)
ZA (1) ZA739534B (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2384773A1 (fr) * 1977-03-25 1978-10-20 Allen & Hanburys Ltd Nouveaux composes heterocycliques a activite spasmolytique
EP1174431A2 (fr) 1997-11-12 2002-01-23 Bayer Aktiengesellschaft 2-Phényl-substitués Imidazotriazinone comme inhibiteurs de la phoshodiesterase
US6930108B2 (en) 2001-07-23 2005-08-16 Bayer Healthcare Ag Use of 2-alkoxyphenol-substituted imidazotriazinones
US6943163B2 (en) 1998-06-20 2005-09-13 Bayer Aktiengesellschaft 7-Alkyl and cycloalkyl-substituted imidazotriazinones

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107309A (en) * 1977-05-23 1978-08-15 American Cyanamid Company Substituted imidazo[1,2-d]-as-triazines
US4096257A (en) * 1977-05-23 1978-06-20 American Cyanamid Company Substituted imidazo [1,2-d]-as-triazines
US4126444A (en) * 1977-11-22 1978-11-21 American Cynamid Company Substituted imidazo (1,5-D)-as-triazin-4-ols, and herbicidal use thereof
US4308384A (en) * 1978-09-18 1981-12-29 Glaxo Group Limited Production of triazinones
DD244681A3 (de) * 1985-12-02 1987-04-15 Zeiss Jena Veb Carl Vorrichtung zur positionierung von enden flexibler lichtleitelemente
US6624181B1 (en) * 1997-02-28 2003-09-23 Altana Pharma Ag Synergistic combination
KR20010072931A (ko) 1998-08-26 2001-07-31 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스 폐 질환 치료 요법
CA2381802C (fr) 1999-08-21 2010-12-07 Byk Gulden Lomberg Chemische Fabrik Gmbh Combinaison synergique de roflumilast et de salmeterol
CA2449163C (fr) * 2001-05-09 2010-07-13 Bayer Healthcare Ag Utilisation nouvelle d'imidazotriazinones 2-phenyl-substituees
GB0113343D0 (en) * 2001-06-01 2001-07-25 Bayer Ag Novel Heterocycles 2
GB0113344D0 (en) 2001-06-01 2001-07-25 Bayer Ag Novel heterocycles 3
DE10130167A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Imidazotriazine
DE10230604A1 (de) * 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
DE10230605A1 (de) * 2002-07-08 2004-01-29 Bayer Ag Substituierte Imidazotriazine
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
ES2326808T3 (es) * 2003-04-01 2009-10-20 Smithkline Beecham Corporation Compuestos de imidazotriazina para el tratamiento de enfermedades cancerosas.
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
DE102005009240A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
EP2258359A3 (fr) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenèse par modulation des récepteurs muscariniques avec sabcomeline
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
KR20080056250A (ko) * 2005-09-29 2008-06-20 바이엘 헬스케어 아게 비뇨기 장애의 치료를 위한 ｐｄｅ 억제제 및 이들의 조합
EP1940389A2 (fr) 2005-10-21 2008-07-09 Braincells, Inc. Modulation de la neurogenese par inhibition de la pde
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
EP1991212A1 (fr) * 2006-03-08 2008-11-19 Braincells, Inc. Modulation de neurogenèse par des agents nootropes
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
MX2008014320A (es) * 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
EP2021000A2 (fr) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenèse par modulation de l'angiotensine
EP2068872A1 (fr) * 2006-09-08 2009-06-17 Braincells, Inc. Combinaisons contenant un dérivé de 4-acylaminopyridine
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2066355A2 (fr) * 2006-09-19 2009-06-10 Braincells, Inc. Combinaison comprenant un agent ppar et un deuxième agent neurogène pour le traitement d'une maladie du système nerveux central, pour augmenter la différentiation neuronale et pour augmenter la neurogenèse
CN101711153A (zh) * 2007-06-13 2010-05-19 拜耳先灵制药股份公司 用于治疗听觉损伤的pde抑制剂
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2804603A1 (fr) 2012-01-10 2014-11-26 President and Fellows of Harvard College Composés promoteurs de réplication des cellules bêta et leurs procédés d'utilisation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2160407A1 (fr) * 1971-11-19 1973-06-29 Allen & Hanburys Ltd

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2160407A1 (fr) * 1971-11-19 1973-06-29 Allen & Hanburys Ltd

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2384773A1 (fr) * 1977-03-25 1978-10-20 Allen & Hanburys Ltd Nouveaux composes heterocycliques a activite spasmolytique
EP1174431A2 (fr) 1997-11-12 2002-01-23 Bayer Aktiengesellschaft 2-Phényl-substitués Imidazotriazinone comme inhibiteurs de la phoshodiesterase
BG65257B1 (bg) * 1997-11-12 2007-10-31 Bayer Aktiengesellschaft 2-фенил-заместени имидазотриазинони като фосфодиестеразни инхибитори
EP2295436A1 (fr) 1997-11-12 2011-03-16 Bayer Schering Pharma AG 2-Phényl-substitués Imidazotriatinone comme inhibiteurs de la phosphodiesterase V
US6943163B2 (en) 1998-06-20 2005-09-13 Bayer Aktiengesellschaft 7-Alkyl and cycloalkyl-substituted imidazotriazinones
US6930108B2 (en) 2001-07-23 2005-08-16 Bayer Healthcare Ag Use of 2-alkoxyphenol-substituted imidazotriazinones
US7276504B2 (en) 2001-07-23 2007-10-02 Bayer Healthcare Ag Use of 2-alkoxyphenyl-substituted imidazotriazinones

Also Published As

Publication number Publication date
NO140301B (no) 1979-04-30
AU6377473A (en) 1975-06-19
AU474078B2 (en) 1976-07-15
US3941785A (en) 1976-03-02
IL43872A0 (en) 1974-03-14
AT336029B (de) 1977-04-12
DE2364076A1 (de) 1974-07-18
FR2213058B1 (fr) 1977-07-01
IE38681B1 (en) 1978-05-10
GB1457873A (en) 1976-12-08
LU69099A1 (fr) 1974-04-02
SE408179B (sv) 1979-05-21
ES422001A1 (es) 1976-08-01
FI57260B (fi) 1980-03-31
NL7400095A (fr) 1974-07-08
IE38681L (en) 1974-07-04
IL43872A (en) 1979-01-31
JPS4995994A (fr) 1974-09-11
CA1005057A (en) 1977-02-08
NO140301C (no) 1979-08-08
CH618170A5 (fr) 1980-07-15
ATA2374A (de) 1976-08-15
FI57260C (fi) 1980-07-10
BE809369A (fr) 1974-07-03
ZA739534B (en) 1974-11-27

Similar Documents

Publication Publication Date Title
AU476761B2 (fr)
AU474593B2 (fr)
AU474511B2 (fr)
AU474838B2 (fr)
AU471343B2 (fr)
AU476714B2 (fr)
AU472848B2 (fr)
AU476696B2 (fr)
AU466283B2 (fr)
AR199451A1 (fr)
AU477823B2 (fr)
AU471461B2 (fr)
AR193950A1 (fr)
AR197627A1 (fr)
AU476873B1 (fr)
AU477824B2 (fr)
AR195311A1 (fr)
AR195948A1 (fr)
AR196382A1 (fr)
AR200256A1 (fr)
AR196123Q (fr)
AR196212Q (fr)
BG19898A1 (fr)
BG19257A1 (fr)
AU479504A (fr)

Legal Events

Date Code Title Description
ST Notification of lapse